Pre-ASM satellite symposium webinar: Treatment advances in cardiorenal disease

17th Annual Scientific Meeting of the Cardiorenal Forum
Pre-ASM satellite symposium webinar
Thursday 6th October 2022 at either 12.30–13.30 or 18.00–19.00 BST (GMT + 1)

Treatment advances in cardiorenal disease


AstraZeneca and Bayer have provided a sponsorship grant towards this independent Programme. AstraZeneca and Bayer have had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence.


As part of our activities for our 17th annual scientific meeting (ASM), we are providing this pre-recorded webinar, without charge, to healthcare professionals, particularly those who are unable to attend our Friday 7th October, face-to-face meeting, although we do hope you will be able to attend both. The webinar will be broadcast twice on Thursday 6th October 2022 at 12.30-13.30 or 18.00-19.00 so choose to tune in at a time to suit you.


What is the webinar about?

The aim of the webinar is to provide an update on:

  • Use of SGLT2 inhibitors in heart failure and chronic kidney disease (CKD)
  • Approaches to treating hyperkalaemia in these populations
  • Overview on developments in mineralocorticoid antagonists

This will cover lessons from recent trials, evolving multidisciplinary guidelines, and future care pathways.

Is it for me?

This webinar is for healthcare professionals only to whom it is offered free of charge. It is aimed at cardiologists, nephrologists, diabetologists, specialist nurses, clinical pharmacists – all grades with a particular on those in training.

Learning objectives

After attending this webinar, delegates will have learned

  • From recent trials on modern-day treatments in heart failure and renal disease
  • The implications of trial results for future practice and guidelines
  • Adapting services for providing optimised care.

Accreditation

The Cardiorenal Forum will issue certificates of attendance after the webinar, which will be equivalent to 1 CPD point.

Endorsements

We are delighted that KDIGO (Kidney Disease Improving Global Outcomes) has endorsed this webinar.




  •   Chairs: Professor Paul Kalra, Consultant Cardiologist, Portsmouth Hospitals University NHS Trust and Professor Philip Kalra, Consultant Nephrologist, Salford Royal NHS Foundation Trust, Professor of Renal Medicine, University of Manchester
  •   Log in available from either 12.00 or 17.30 BST (GMT +1)
  •   Introduction 12.30 or 18.00 BST (GMT +1)
  •   SGLT2 inhibitors and the cardiorenal patient
    David Wheeler, Professor of Kidney Medicine, University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust
  •   Treatment of hyperkalaemia in heart and kidney patients
    Patricia Campbell, Consultant Cardiologist/Heart Failure Lead, Southern Health and Social Care Trust, Northern Ireland
  •   The evolving role of mineralocorticoid antagonists in cardiorenal medicine
    Debasish Banerjee, Professor of Clinical Practice-Renal Medicine, St George’s, University of London
  •   Webinar close 13.30 or 19.00 BST (GMT +1)


   

Professor Debasish Banerjee Professor of Clinical Practice-Renal Medicine, St George’s University Hospitals, NHS Foundation Trust

Professor Debasish Banerjee is Consultant Nephrologist, Professor of Clinical Practice – Renal Medicine, St George’s University Hospitals, NHS Foundation Trust. Debasish is a clinical nephrologist managing CKD, dialysis and kidney transplant patients and he has much expertise in management of CKD patients with cardiovascular disease, hypertension, heart failure and diabetes

Dr Patricia Campbell Consultant Cardiologist/Heart Failure Lead, Southern Health and Social Care Trust, Northern Ireland

Dr Patricia Campbell is Consultant Cardiologist/Heart Failure Lead, Southern Health and Social Care Trust, Northern Ireland. Patricia is widely published and involved in clinical Heart Failure trials, and was elected to the Board of the British Society of Heart Failure, this year

Professor Paul Kalra Consultant Cardiologist, Portsmouth Hospitals University NHS Trust

Professor Paul Kalra is a Consultant Cardiologist at Portsmouth Hospitals University NHS Trust, and an Honorary Professor of Cardiology. His research interests include the role of iron deficiency and its correction in patients with heart failure, cardiorenal disease and the impact of hyperkalaemia on RAAS inhibition use. He is one of the founders of the Cardiorenal Forum and past Chair of the British Society for Heart Failure

Professor Philip Kalra Consultant Nephrologist, Salford Royal NHS Foundation Trust, Professor of Renal Medicine, University of Manchester

Professor Philip Kalra graduated from Cambridge University and is Professor of Nephrology in Salford and the University of Manchester. He has been a Consultant Nephrologist since 1995, working at the Salford Royal NHS Foundation Trust. He has major research focus on renovascular disease, cardiovascular disease in chronic kidney disease (CKD), CKD progression and iron use in CKD, and he leads the research team in Salford. He was Academic Vice President of the UK Renal Association from 2016–19, Chair of the UK Kidney Research Consortium during this time and was Chair of the NIHR CRN Renal Disorders group from 2010–18. He has been involved in the development of several large UK clinical trials in nephrology and cardiology, including the ASTRAL, PIVOTAL and IRONMAN trials, and he has played a role in amalgamating Cardiorenal education and research within the UK

Professor David Wheeler Professor of Kidney Medicine, University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust

Professor David Wheeler is Professor of Kidney Medicine at University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust. Other roles include National Institute for Health and Care Research (NIHR) National Specialty Lead for Renal Disorders. He has been the principle or co-investigator in number clinical trials assessing the effectiveness of therapeutic interventions in people with chronic kidney disease